蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性

doi:10.3969/j.issn.1004-616x.2021.04.006

Abstract

Abstract: OBJECTIVE: To evaluate expressions of protein tyrosine phosphatase receptor J (PTPRJ) in breast cancer tissues and their roles in clinical process. METHODS: The immunohistochemical SP method was used to detect expressions of PTPRJ in normal breast and breast cancer tissues. Then,relationships between PTPRJ expressions,and clinicopathological parameters and survival prognosis of breast cancer patients were analyzed. RESULTS: Results from immunohistochemical staining show that expressions of PTPRJ in normal breast tissues were significantly higher than that in breast cancer tissues (P=0.003). PTPRJ expressions were significantly correlated with lymph node metastasis (P=0.014),TNM stages (P=0.003) and ER status (P=0.048). Kaplan-Meier analyses reveal that breast cancer patients with low PTPRJ expressions in tumors had significantly worse overall survival rates than those with higher PTPRJ expressions (P=0.002). Multivariate analyses show that TNM stages and PTPRJ expressions were independent survival predictors. CONCLUSION: Our data indicates that expressions of PTPRJ were reduced in breast cancer tissues and were closely related to tumor progression. Therefore,PTPRJ expression can possibly be used as a valuable marker for prognosis in patients with breast cancers.

Key words: breast cancer, protein tyrosine phosphatase receptor J, immunohistochemistry, prognosis

CLC Number:

R737.31

ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.

References

[1] SU NG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] ESTEVA F J, HUBBARD-LUCEY V M, TANG J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer[J]. Lancet Oncol, 2019, 20(3):e175-e186.
[3] MARUTHANILA V L, ELANCHERAN R, KUNNUMAKKARA A B, et al. Recent development of targeted approaches for the treatment of breast cancer[J]. Breast Cancer, 2017, 24(2):191-219.
[4] SPRING K, FOURNIER P, LAPOINTE L, et al. The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis[J]. Oncogene, 2015, 34(44):5536-5547.
[5] TAKAHASHI K, MATAFONOV A, SUMARRIVA K, et al. CD148 tyrosine phosphatase promotes cadherin cell adhesion[J]. PLoS One, 2014, 9(11):e112753.
[6] FOURNIER P, DUSSAULT S, FUSCO A, et al. Tyrosine phosphatase PTPRJ/DEP-1 is an essential promoter of vascular permeability, angiogenesis, and tumor progression[J]. Cancer Res, 2016, 76(17):5080-5091.
[7] ZHANG X F, TU R F, LI K K, et al. Tumor suppressor PTPRJ is a target of miR-155 in colorectal cancer[J]. J Cell Biochem, 2017, 118(10):3391-3400.
[8] LUO X L, YANG S Y, ZHOU C W, et al. microRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma[J]. Onco Targets Ther, 2015, 8:3159-3167.
[9] D'AGOSTINO S, LANZILLOTTA D, VARANO M, et al. The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells[J]. Oncotarget, 2018, 9(34):23334-23348.
[10] YAN C M, ZHAO Y L, CAI H Y, et al. Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A[J]. Oncol Rep, 2015, 33(4):1737-1744.
[11] KRESINSKY A, BAUER R, SCHNÖDER T M, et al. Loss of DEP-1(PTPRJ) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia[J]. Haematologica, 2018, 103(11):e505-e509.
[12] SUN Y T, LI S, YU W B, et al. CD148 serves as a prognostic marker of gastric cancer and hinders tumor progression by dephosphorylating EGFR[J]. J Cancer, 2020, 11(9):2667-2678.
[13] 赵瑞君, 谢春伟, 陈戈, 等. PTP1B在ER阳性乳腺癌中的表达及临床预后意义[J]. 临床与实验病理学杂志, 2016, 32(5):492-495.
[14] CUZICK J, SESTAK I, THORAT M A. Impact of preventive therapy on the risk of breast cancer among women with benign breast disease[J]. Breast, 2015, 24(Suppl 2):S51-S55.
[15] CHEN S, IBRAHIM N K, YAN Y, et al. Risk stratification in patients with advanced-stage breast cancer by pretreatment[(18) F]FDG PET/CT[J]. Cancer, 2015, 121(22):3965-3974.
[16] SMART C E, ASKARIAN AMIRI M E, WRONSKI A, et al. Expression and function of the protein tyrosine phosphatase receptor J (PTPRJ) in normal mammary epithelial cells and breast tumors[J]. PLoS One, 2012, 7(7):e40742.
[17] KEANE M M, LOWREY G A, ETTENBERG S A, et al. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells[J]. Cancer Res, 1996, 56(18):4236-4243.
[18] BALAVENKATRAMAN K K, JANDT E, FRIEDRICH K, et al. DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients[J]. Oncogene, 2006, 25(47):6319-6324.

Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[2]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[3]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[4]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[5]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[6]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[7]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[8]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[9]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[10]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[11]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[12]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[13]	SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443.
[14]	DING Yawen, JIAO Wenjing, WANG Pengyu, LU Gang, MA Ming. Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 464-468,489.
[15]	YANG Xiuyuan, PAN Yuelong. Expression of CD10 protein in colorectal carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 344-349.